TWI864053B - 用於製備無菌眼用水性丙酸氟替卡松ａ型奈米晶體懸浮液之方法 - Google Patents

用於製備無菌眼用水性丙酸氟替卡松ａ型奈米晶體懸浮液之方法 Download PDF

Info

Publication number
TWI864053B
TWI864053B TW109124497A TW109124497A TWI864053B TW I864053 B TWI864053 B TW I864053B TW 109124497 A TW109124497 A TW 109124497A TW 109124497 A TW109124497 A TW 109124497A TW I864053 B TWI864053 B TW I864053B
Authority
TW
Taiwan
Prior art keywords
fluticasone propionate
nanocrystals
nanosuspension
aqueous
phase
Prior art date
Application number
TW109124497A
Other languages
English (en)
Chinese (zh)
Other versions
TW202116326A (zh
Inventor
讓 米歇爾 布科夫斯基
阿克沙伊 納德卡尼
荷西 Ｌ 博耶
查克倫 布里吉特 杜克羅斯瓦
湯瑪斯 納芙拉蒂爾
Original Assignee
美商尼科斯眼藥公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 美商尼科斯眼藥公司 filed Critical 美商尼科斯眼藥公司
Publication of TW202116326A publication Critical patent/TW202116326A/zh
Application granted granted Critical
Publication of TWI864053B publication Critical patent/TWI864053B/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/567—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in position 17 alpha, e.g. mestranol, norethandrolone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A61K31/569—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone substituted in position 17 alpha, e.g. ethisterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/186—Quaternary ammonium compounds, e.g. benzalkonium chloride or cetrimide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/04—Artificial tears; Irrigation solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J31/00—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring
    • C07J31/006—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring not covered by C07J31/003

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Ophthalmology & Optometry (AREA)
  • Inorganic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dispersion Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Nanotechnology (AREA)
  • Medical Informatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Biophysics (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
TW109124497A 2019-07-23 2020-07-21 用於製備無菌眼用水性丙酸氟替卡松ａ型奈米晶體懸浮液之方法 TWI864053B (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201962877599P 2019-07-23 2019-07-23
US62/877,599 2019-07-23
US201962942551P 2019-12-02 2019-12-02
US62/942,551 2019-12-02

Publications (2)

Publication Number Publication Date
TW202116326A TW202116326A (zh) 2021-05-01
TWI864053B true TWI864053B (zh) 2024-12-01

Family

ID=71738074

Family Applications (1)

Application Number Title Priority Date Filing Date
TW109124497A TWI864053B (zh) 2019-07-23 2020-07-21 用於製備無菌眼用水性丙酸氟替卡松ａ型奈米晶體懸浮液之方法

Country Status (23)

Country Link
US (3) US20220241296A1 (enExample)
EP (1) EP3769753B1 (enExample)
JP (2) JP7021301B2 (enExample)
KR (1) KR20220038443A (enExample)
CN (2) CN111821261B (enExample)
AU (1) AU2020317084A1 (enExample)
CA (1) CA3145055A1 (enExample)
CY (1) CY1124930T1 (enExample)
DK (1) DK3769753T3 (enExample)
ES (1) ES2905793T3 (enExample)
HR (1) HRP20220165T1 (enExample)
HU (1) HUE057416T2 (enExample)
LT (1) LT3769753T (enExample)
MD (1) MD3769753T2 (enExample)
MX (1) MX420447B (enExample)
PH (1) PH12022550003A1 (enExample)
PL (1) PL3769753T3 (enExample)
PT (1) PT3769753T (enExample)
RS (1) RS62932B1 (enExample)
SI (1) SI3769753T1 (enExample)
SM (1) SMT202200082T1 (enExample)
TW (1) TWI864053B (enExample)
WO (1) WO2021014348A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3769753B1 (en) * 2019-07-23 2021-11-17 Nicox Ophthalmics, Inc. Process for the preparation of sterile ophthalmic aqueous fluticasone propionate form a nanocrystals suspensions
CN115887372A (zh) * 2022-10-25 2023-04-04 苏州欧康维视生物科技有限公司 丙酸氟替卡松混悬液及其制备方法
CN115554238A (zh) * 2022-10-25 2023-01-03 苏州欧康维视生物科技有限公司 眼用混悬液及其制备方法

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104350063A (zh) * 2012-05-08 2015-02-11 埃塞克斯治疗公司 疏水性治疗剂的制剂、其制备方法及应用

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU674852B2 (en) * 1992-05-06 1997-01-16 Alcon Laboratories, Inc. Use of borate-polyol complexes in ophthalmic compositions
JP3450805B2 (ja) * 2000-08-08 2003-09-29 わかもと製薬株式会社 水性医薬組成物
US6900184B2 (en) * 2003-04-14 2005-05-31 Wyeth Holdings Corporation Compositions containing pipercillin and tazobactam useful for injection
US20060229219A1 (en) * 2005-04-11 2006-10-12 Advanced Medical Optics, Inc. Borate-polyol mixtures as a buffering system
US8010032B2 (en) * 2005-05-23 2011-08-30 Xerox Corporation Fuser member comprising deflocculated material
US20110105450A1 (en) * 2009-06-05 2011-05-05 Aciex Therapeutics, Inc. Ophthalmic formulations of fluticasone and methods of use
TWI489997B (zh) 2009-06-19 2015-07-01 Alcon Res Ltd 含有硼酸－多元醇錯合物之水性藥學組成物
WO2013025696A1 (en) 2011-08-15 2013-02-21 Teva Pharmaceutical Industries Ltd. Ophthalmic formulations and processes for their preparation
JP6294893B2 (ja) * 2012-12-17 2018-03-14 グラクソ グループ リミテッドＧｌａｘｏ Ｇｒｏｕｐ Ｌｉｍｉｔｅｄ 炎症性及び／又はアレルギー性の状態を治療するためのレボカバスチンとフルチカゾンフランカルボン酸エステルとの併用
TWI773641B (zh) 2015-05-08 2022-08-11 日商活效製藥股份有限公司 含有糖皮質類固醇（ｇｌｕｃｏｃｏｒｔｉｃｏｉｄｓ）之奈米微粒子之水性懸浮液劑
EP3769753B1 (en) * 2019-07-23 2021-11-17 Nicox Ophthalmics, Inc. Process for the preparation of sterile ophthalmic aqueous fluticasone propionate form a nanocrystals suspensions

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104350063A (zh) * 2012-05-08 2015-02-11 埃塞克斯治疗公司 疏水性治疗剂的制剂、其制备方法及应用

Also Published As

Publication number Publication date
US20220241296A1 (en) 2022-08-04
LT3769753T (lt) 2022-05-10
HUE057416T2 (hu) 2022-05-28
MX420447B (es) 2025-02-10
PT3769753T (pt) 2022-02-15
US20220323352A1 (en) 2022-10-13
MD3769753T2 (ro) 2022-04-30
JP7021301B2 (ja) 2022-02-16
TW202116326A (zh) 2021-05-01
US11406596B2 (en) 2022-08-09
PH12022550003A1 (en) 2022-11-14
CA3145055A1 (en) 2021-01-28
EP3769753A1 (en) 2021-01-27
US20210023001A1 (en) 2021-01-28
KR20220038443A (ko) 2022-03-28
HRP20220165T1 (hr) 2022-04-29
SMT202200082T1 (it) 2022-03-21
PL3769753T3 (pl) 2022-04-04
SI3769753T1 (sl) 2022-04-29
JP7494230B2 (ja) 2024-06-03
CN111821261A (zh) 2020-10-27
CN115120557A (zh) 2022-09-30
ES2905793T3 (es) 2022-04-12
CY1124930T1 (el) 2023-01-05
AU2020317084A1 (en) 2022-03-03
RS62932B1 (sr) 2022-03-31
JP2021017449A (ja) 2021-02-15
WO2021014348A1 (en) 2021-01-28
CN115120557B (zh) 2024-05-07
EP3769753B1 (en) 2021-11-17
JP2022062172A (ja) 2022-04-19
DK3769753T3 (da) 2022-01-31
MX2022000928A (es) 2022-02-22
CN111821261B (zh) 2022-07-26

Similar Documents

Publication Publication Date Title
JP5558582B2 (ja) 眼科用医薬組成物の調製方法
JP6542193B2 (ja) 後眼部へ薬物を送達するための眼用製剤
CN107847432A (zh) D2o稳定化的药物制剂
JP2019535798A (ja) 眼科用活性医薬成分送達のためのシクロデキストリン固体複合体の製造
US20220323352A1 (en) Process for the preparation of sterile ophthalmic aqueous fluticasone propionate form a nanocrystals suspensions
JP7716996B2 (ja) 薬剤を含む水性組成物のｐＨを安定化させるための方法
CN107613985A (zh) 含有糖皮质激素的纳米微粒的水性悬浮液剂
KR102450020B1 (ko) 약물 전달 및 전안부 보호를 위한 안구용 제제
CN104814924A (zh) 一种布佐林胺脂质体眼用制剂及其制备方法
CN102665730A (zh) 眼用制剂及其制造方法
CN104721136A (zh) 一种布佐林胺眼用纳米混悬剂及其制备方法
HK40077423A (en) Process for the preparation of sterile ophthalmic aqueous fluticasone propionate form a nanocrystals suspensions
CN104721130B (zh) 一种布林佐胺包合物眼用制剂及其制备方法
HK40038382B (en) Process for the preparation of sterile ophthalmic aqueous fluticasone propionate form a nanocrystals suspensions
HK40038382A (en) Process for the preparation of sterile ophthalmic aqueous fluticasone propionate form a nanocrystals suspensions
HK40077423B (zh) 用於制备无菌眼用水性丙酸氟替卡松a型纳米晶体混悬液的方法
CN106714803A (zh) 眼用混悬液制剂
WO2025144421A1 (en) Aqueous nanomicelle ophthalmic formulations containing difluprednate
EA050512B1 (ru) СПОСОБ СТАБИЛИЗАЦИИ рН ВОДНОЙ КОМПОЗИЦИИ, СОДЕРЖАЩЕЙ ЛЕКАРСТВЕННОЕ СРЕДСТВО
HK1233540B (zh) 眼用混悬液制剂
HK1234413B (zh) 用於治療眼部病症的膜附著性自組裝體系